CONATUS PHARMACEUTICALS INC. (NASDAQ:CNAT) Files An 8-K Entry into a Material Definitive Agreement

CONATUS PHARMACEUTICALS INC. (NASDAQ:CNAT) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01


Conatus Pharmaceuticals Inc. Exhibit
EX-10.1 2 d800416dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 AMENDMENT TO OPTION,…
To view the full exhibit click here

Story continues below

About CONATUS PHARMACEUTICALS INC. (NASDAQ:CNAT)

Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.

An ad to help with our costs